|1.||Usui, Isao: 3 articles (02/2013 - 11/2009)|
|2.||Urakaze, Masaharu: 3 articles (02/2013 - 11/2009)|
|3.||Matsuya, Yuji: 3 articles (02/2013 - 11/2009)|
|4.||Hayashi, Ryuji: 3 articles (02/2013 - 11/2009)|
|5.||Imanishi, Shingo: 3 articles (02/2013 - 11/2009)|
|6.||Tobe, Kazuyuki: 3 articles (02/2013 - 11/2009)|
|7.||Sundar, Isaac K: 2 articles (01/2014 - 06/2012)|
|8.||Yao, Hongwei: 2 articles (01/2014 - 06/2012)|
|9.||Rahman, Irfan: 2 articles (01/2014 - 06/2012)|
|10.||Ichikawa, Tomomi: 2 articles (02/2013 - 06/2012)|
08/01/2015 - "During the induction of emphysema in rats, administration of SRT1720 improved lung function including airway resistance and pulmonary dynamic compliance. "
08/01/2015 - "SRT1720 could protect against AECII apoptosis in rats with emphysema and thus could be used in COPD treatment."
08/01/2015 - "Lung injury caused by emphysema was alleviated after SRT1720 treatment. "
08/01/2015 - "The main aim of this study was to investigate whether SRT1720, a pharmacological SIRT1 activator, could protect against AECII apoptosis in rats with emphysema caused by cigarette smoke exposure and intratracheal lipopolysaccharide instillation in vivo. "
08/01/2015 - "Sirtuin 1 Activator SRT1720 Protects Against Lung Injury via Reduction of Type II Alveolar Epithelial Cells Apoptosis in Emphysema."
12/15/2014 - "SIRT1 activation with SRT1720 ameliorates vascular endothelial dysfunction with aging in mice by enhancing COX-2 signaling and reducing oxidative stress and inflammation. "
07/27/2014 - "SRT1720 treatment enhanced energy metabolism by stimulating mitochondrial biogenesis as well as decreasing nitrosative stress and inflammation, thereby attenuating I/R-induced renal injury."
01/01/2014 - "Targeted deletion of Bmal1 in lung epithelium augmented inflammation in response to CS, which was not attenuated by the selective SIRT1 activator SRT1720 (EC50=0.16 μM) in these mice. "
12/15/2014 - "The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice."
12/01/2011 - "The sirtuin literature focuses on pharmacological activators of SIRT1 (e.g., resveratrol, SRT1720), proposed as therapeutics for diabetes, neurodegeneration, inflammation, and others. "
|3.||Metabolic Diseases (Metabolic Disease)
03/13/2014 - "We found extension in lifespan, delayed onset of age-related metabolic diseases, and improved general health in mice fed a standard diet after SRT1720 supplementation. "
11/01/2010 - "Resveratrol and SRT1720 have been shown to act as sirtuin activators that may ameliorate type 2 diabetes and metabolic diseases in mice. "
07/15/2015 - "The observation that SRT1720, inhibiting ER stress, was able to counteract GlcN effects lays the basis for future studies aimed to exploit this drug and cognate compounds in the treatment of endothelial dysfunction and atherosclerosis."
10/02/2015 - "In this model, administration of the SIRT1 agonist SRT1720 substantially attenuated AngII-accelerated atherosclerosis with decreasing blood pressure and inhibited NF-κB and STAT3 activation, which was associated with suppression of inflammatory factor and atherogenic gene expression in the artery. "
10/02/2015 - "The Sirt1 activator SRT1720 attenuates angiotensin II-induced atherosclerosis in apoE⁻/⁻ mice through inhibiting vascular inflammatory response."
|1.||Sodium Glutamate (Accent)
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Caspase 8 (Caspase-8)
|7.||Caspase 3 (Caspase-3)
|8.||Reactive Oxygen Species (Oxygen Radicals)
|9.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|10.||checkpoint kinase 2
|1.||Homologous Transplantation (Allograft)